IPO/FPO Analysis
IPO and FPO reviews — what the numbers say before you subscribe.
127 articles
-
Inox India IPO Review: Expensive player in niche industry
INOX India Limited was established in 1976 and has more than 30 years of experience in the development, design, manufacture and installation of equipment and systems for cryogenic conditions.
-
DOMS Industries IPO Review: Avoid, as growth is already priced in
Doms Industries engages in the design, development, manufacturing, and sale of a diverse range of stationery and art products.
-
Tata Technologies IPO Review- Niche player in an exciting space
Tata Technologies Limited (TTL) operates globally in engineering, research, and development (ER&D) services, mainly focused on automotive, aerospace, and transportation and construction heavy machinery (TCHM) sectors.
-
Mamaearth IPO Review – Beauty, Brands, and Growth
Honasa Consumer was established in 2016 by the husband-wife duo Varun and Ghazal Alagh, renowned for their appearance on Shark Tank.
-
JSW Infrastructure IPO Review – Ports, Prospects, and Progress
JSW Infrastructure Limited (JSWIL) is the second largest commercial port operator in India (in terms of cargo handling capacity in FY23).
-
Yatra Online IPO Review
Yatra Online Ltd, is India’s largest corporate travel services provider in terms of the number of corporate clients and the third largest online travel company in India among key OTA players in…
-
TVS Supply Chain Solutions IPO Review
TVS Supply Chain Solutions (TSCS) is an Indian multinational, part of TVS Mobility Group, providing integrated supply chain solutions (ISCS).
-
Concord Biotech IPO Review
Concord Biotech is a niche biopharma company manufacturing APIs (active pharmaceutical ingredients) and formulations for select therapeutic areas.
-
Cyient DLM Limited IPO Review – A Play on the India Electronics Manufacturing Theme
Purpose of IPO: Fresh Issue for repayment of debt & working capital requirements.
-
Mankind Pharma IPO Review
Mankind Pharma is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
-
KFin Technologies IPO Review
The company will not receive any proceeds and proceeds will go to the Promoter Shareholder selling.
-
LIC IPO Review
The company will not receive any proceeds from the listing as it is purely an offer for sale.
